Exploratory Study Assessing Synchronisation of Egg Sacs With Degarelix

For the primary end-point (data collected on Stimulation Day 1), the study will compare degarelix 2.5 mg administered in the mid-luteal phase to placebo administered in the mid-luteal phase.

After Stimulation Day 1 the placebo group will be split into two groups: a degarelix 2.5 mg follicular group and a ganirelix 0.25 mg group.

Inclusion criteria

• Signed Informed Consent Form, prior to screening evaluations
• In good physical and mental health
• Pre-menopausal females between the ages of 18-35 years (both inclusive) at the time of randomisation
• Regular menstrual cycles of 26-35 days duration (both inclusive), presumed to be ovulatory
• Body mass index (BMI) between 18 and 29 kg/m2 (both inclusive)
• Willing to donate the retrieved oocytes
• Willing to use an adequate barrier method of contraception from informed consent to Day hCG injection +7 and to use an adequate barrier or hormonal method of contraception from Day hCG injection +7 to the end-of-study visit

Exclusion criteria

• Abnormal karyotype
• Any known clinically significant systemic disease (e.g., insulin dependent diabetes)
• Any known endocrine or metabolic abnormalities (pituitary, adrenal, pancreas, liver or kidney) which can compromise participation in the study
• Diagnosed with polycystic ovarian syndrome or endometriosis stage III/IV
• Diagnosed as "poor responder"
• History of recurrent miscarriage (defined as three consecutive spontaneous losses before weeks 24 of pregnancy)
• Pregnancy or lactation
• Use of any investigational drug during 3 months prior to start of the current COH cycle
• Previous participation in the study
• Hypersensitivity to any trial product